Serono Luveris Data Support Follicular Development Indication, Cmte. Says
Executive Summary
Serono's Luveris data are sufficient to support a follicular development indication in infertile hypogonadotropic hypogonadal women with severe luteinizing hormone deficiency, FDA's Reproductive Health Drugs Advisory Committee said Sept. 30
You may also be interested in...
Product Withdrawal Can Be As Hard As Approval: Luveris' 4-Year Journey Ends
EMD Serono had not marketed the infertility treatment in US since 2012, when it first asked FDA to withdraw application; company was unable to complete confirmatory trial required under accelerated approval.
Serono Infertility Treatment Luveris Clears FDA
Serono will study the effect of the recombinant luteinizing hormone infertility treatment Luveris on time to clinical pregnancy as a Phase IV commitment
Serono Infertility Treatment Luveris Clears FDA
Serono will study the effect of the recombinant luteinizing hormone infertility treatment Luveris on time to clinical pregnancy as a Phase IV commitment